Spero Therapeutics spent a decade building an oral carbapenem and then, within weeks of approval, sold most of the economics to fund a different company. Mid-June, the Food and Drug Administration cleared Utebzi for adults with complicated urinary tract infections who have few remaining oral options, making it the first oral carbapenem on the United States market. GSK already owns commercialization outside selected Asian territories. Rather than wait for a royalty stream to accrue, Spero turned around in July and pledged a slice of those GSK payments to HealthCare Royalty in exchange for $105 million of senior notes. The same week, it paid Innovent $35 million for worldwide rights, excluding Greater China, to SP001, a third-generation antibody against CD40 ligand. The stock still trades as if the antibiotic chapter never closed. The operating company has already moved on. That gap between the listing story and the operating story is the entire equity debate.
The tension is structural, not cosmetic. The notes carry a ten percent coupon and a nine-year term, and they sit in front of almost every GSK dollar until they are repaid. After that, Spero keeps only a thirty-five percent residual interest in later milestone and royalty payments. Professional and legal fees already pushed general and administrative costs above research spending in the latest quarter, a tell that the company was buying a new identity rather than running a late-stage antibiotic program. Amgen's Uplizna already holds the first approved IgG4-related disease label after a large flare-risk reduction in the MITIGATE trial. SP001 enters that market as a Phase Two-ready molecule with healthy-volunteer and Sjogren data, not with a registrational package. The antibody is a design hypothesis competing with an approved depleter, not a second franchise already in hand.
Cash at quarter-end sat just above $50 million before the royalty close and before the Innovent check. Management states that the combined proceeds, net of that upfront, fund operations into the back half of twenty twenty-nine. The latest quarter printed no revenue and a wider loss as collaboration and grant lines ran off. That print is the trough of the old model, not the start of the new one. The question the next year resolves is whether GSK's launch generates enough pledged cash to service the notes while Spero converts an in-licensed antibody into a credible IgG4-related disease study, or whether the market is correctly treating both legs as thin options on a small equity.